Drugs / Imdusiran
Imdusiran
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06154278 | Jul 2024 → Dec 2026 expected | chronic hepatitis B virus infection | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT06245291 | May → Aug 2024 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04980482 | Oct 2021 → Mar 2025 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT04820686 | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04847440 | Mar 2021 → Sep 2022 | chronic hepatitis B virus infection, hepatitis D virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-10 | Assembly Biosciences | Results Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting® assemblybio.com ↗
Additionally, the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 provide further insights that may inform future studies for the HBV and liver disease scientific community. |
| 2022-11-04 | Assembly Biosciences | Results Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV assemblybio.com ↗
Clinical results from the study evaluating first-generation core inhibitor vebicorvir (VBR) in combination with Arbutus Biopharma’s AB-729 in HBV are presented in the late-breaking poster entitled “Evaluation of the vebicorvir, NrtI, and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: Interim analysis from an open label phase 2 study.” |
All press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imdusiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154278 ↗ |
| Known as | AB-729 | “Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection” NCT06245291 ↗ |
| Known as | AB-729 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314644 ↗ |
| Action | Inhibit | “AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV.” NCT04820686 ↗ |
| Modality | Small interfering RNA (siRNA) | “AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV.” NCT04820686 ↗ |
| Route | Subcutaneous | “Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.” NCT04820686 ↗ |